KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis.Cancer medicine · 2019
   Pooled it
2. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.Cancer medicine · 2014
   Pooled it
3. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2015
   Trial
4. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
   Trial
5. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.BMC cancer · 2012
   Trial
6. Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.Human cell · 2021
   Article
7. The Advance and Correlation ofPathology oncology research : POR · 2021
   Review
8. KRAS polymorphisms are associated with survival of CRC in Chinese population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
   Article
9. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.Oncotarget · 2016
   Review
10. The hallmarks of premalignant conditions: a molecular basis for cancer prevention.Seminars in oncology · 2016
    Review
11. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Article
12. The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.OncoTargets and therapy · 2014
    Article
13. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer.Cancer management and research · 2014
    Review
14. SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.Critical reviews in oncogenesis · 2013
    Review

Corrections and comments

• Comment on
  A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.2011

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as